OSIRonline.org - Amylin, Orient-Express, PFG, Sun: U.S. Equity Movers (Correct) - Bloomberg
Nov. 4 (Bloomberg) — The following companies are having unusual price changes in U.S. trading today. Stock symbols are in parentheses, and share prices are as of 12:15 p.m. in New York. Amylin Pharmaceuticals Inc. (AMLN US) retreated 21 percent to
Source: www.bloomberg.com
UPDATE 1-Genzyme, Osiris to develop stem cell products - Reuters
Nov 4 (Reuters) - Genzyme Corp (GENZ.O: Quote , Profile , Research , Stock Buzz ) said it would co-develop and market two adult stem cell products of Osiris Therapeutics (OSIR.O: Quote , Profile , Research , Stock Buzz ) that are being tested for
Source: www.reuters.com
Osiris Therapeutics to Present at the Rodman & Renshaw 10th Annual - PR Inside
2008-11-09 23:53:01 - Rodman & Renshaw Annual Global Investment Conference - Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory
Source: www.pr-inside.com
Osiris Therapeutics stock up 25% - Washington Business Journal
Shares of Osiris Therapeutics Inc. surged Tuesday after the announcement of a development partnership with Genzyme Corp. for two stem-cell treatments. Stock in Columbia, Md.-based Osiris (NASDAQ: OSIR) gained $4 (26 percent) to $19.50 apiece, by 8:30
Source: washington.bizjournals.com
Genzyme, Osiris ink $1B deal - Boston Business Journal
Genzyme Corp. has signed an alliance with stem cell company Osiris Therapeutics to develop two new treatments. Assuming the drugs reach the marketplace, the arrangement could cost Genzyme up to $1.25 billion in development, regulatory and sales
Source: boston.bizjournals.com